X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (62) 62
male (56) 56
female (53) 53
aged (50) 50
index medicus (49) 49
middle aged (47) 47
oncology (47) 47
lung neoplasms - drug therapy (42) 42
carcinoma, non-small-cell lung - drug therapy (36) 36
adult (35) 35
chemotherapy (32) 32
lung cancer (23) 23
lung cancer, non-small cell (23) 23
lung neoplasms - pathology (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
cancer (20) 20
care and treatment (19) 19
non-small cell lung cancer (19) 19
respiratory system (19) 19
treatment outcome (19) 19
mutation (18) 18
analysis (15) 15
gefitinib (15) 15
aged, 80 and over (14) 14
neoplasm staging (14) 14
antineoplastic agents - therapeutic use (13) 13
disease-free survival (13) 13
lung neoplasms - genetics (13) 13
lung neoplasms - mortality (13) 13
carboplatin (12) 12
carcinoma, non-small-cell lung - genetics (12) 12
cancer therapies (11) 11
carboplatin - administration & dosage (11) 11
cisplatin (11) 11
docetaxel (11) 11
hematology, oncology and palliative medicine (11) 11
therapy (11) 11
antineoplastic agents - adverse effects (10) 10
carcinoma, non-small-cell lung - mortality (10) 10
carcinoma, non-small-cell lung - pathology (10) 10
lung cancer, small cell (10) 10
pulmonary/respiratory (10) 10
research (10) 10
clinical trials (9) 9
medical research (9) 9
nivolumab (9) 9
non-small-cell lung cancer (9) 9
original (9) 9
paclitaxel - administration & dosage (9) 9
pharmaceuticals (9) 9
trial (9) 9
tyrosine (9) 9
adenocarcinoma - drug therapy (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
cisplatin - administration & dosage (8) 8
drug combinations (8) 8
epidermal growth factor (8) 8
erlotinib (8) 8
japan (8) 8
kaplan-meier estimate (8) 8
medicine, experimental (8) 8
multicenter (8) 8
original article (8) 8
paclitaxel (8) 8
patients (8) 8
safety (8) 8
acquired-resistance (7) 7
antineoplastic agents - administration & dosage (7) 7
asian continental ancestry group (7) 7
drug administration schedule (7) 7
epidermal growth factor receptors (7) 7
metastasis (7) 7
non-small cell lung carcinoma (7) 7
oncology, experimental (7) 7
open-label (7) 7
original articles (7) 7
protein kinase inhibitors - therapeutic use (7) 7
protein-tyrosine kinase (7) 7
survival rate (7) 7
toxicity (7) 7
tumors (7) 7
adenocarcinoma (6) 6
bevacizumab (6) 6
clinical research (6) 6
follow-up studies (6) 6
neoplasm recurrence, local - drug therapy (6) 6
nsclc (6) 6
oxonic acid - administration & dosage (6) 6
platinum (6) 6
retrospective studies (6) 6
tegafur - administration & dosage (6) 6
adenocarcinoma - pathology (5) 5
alectinib (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
apoptosis (5) 5
biopsy (5) 5
cancer research (5) 5
carcinoma, squamous cell - drug therapy (5) 5
chemoradiotherapy (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 11/2016, Volume 27, Issue suppl_7
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 2, pp. 121 - 128
Journal Article
Cancer Science, ISSN 1347-9032, 02/2016, Volume 107, Issue 2, pp. 162 - 167
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1000 - 1006
Journal Article
Cancer Science, ISSN 1347-9032, 11/2016, Volume 107, Issue 11, pp. 1642 - 1646
Journal Article
Cancer Science, ISSN 1347-9032, 07/2017, Volume 108, Issue 7, pp. 1368 - 1377
In pathway‐targeted cancer drug therapies, the relatively rapid emergence of drug‐tolerant persisters ( DTP s) substantially limits the overall therapeutic... 
Cell interaction | stem‐like cells | senescent cells | TKI | drug resistance | EGFR | stem-like cells | EGFR-TKI | GEFITINIB | ACQUIRED-RESISTANCE | MECHANISMS | CHEMOTHERAPY | CELL LUNG-CANCER | EGFR INHIBITORS | IN-VITRO | ONCOLOGY | SENESCENCE | ERLOTINIB | Adenocarcinoma | Adenocarcinoma of Lung | Carcinoma, Non-Small-Cell Lung | Neoplastic Stem Cells - drug effects | Humans | Cellular Senescence - drug effects | Lung Neoplasms | Flow Cytometry | Phloretin - pharmacology | Polymerase Chain Reaction | Neoplastic Stem Cells - pathology | Gefitinib | Molecular Targeted Therapy - methods | ErbB Receptors - antagonists & inhibitors | Blotting, Western | Xenograft Model Antitumor Assays | Animals | Withanolides - pharmacology | Mice, Nude | Cell Line, Tumor | Glucose - metabolism | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - physiology | Tyrosine | Glucose metabolism | Epidermal growth factor | Analysis | Stem cells | Physiological aspects | Phenols | Transplantation | Glucose | Drug resistance | Dextrose | Flow cytometry | Phenotypes | Senescence | Epidermal growth factor receptors | Lung cancer | Tumor cell lines | Metabolism | Kinases | Gene expression | Cancer therapies | Proteins | Cell lines | Population | Protein-tyrosine kinase receptors | Mutation | Protein-tyrosine kinase | Original | EGFR‐TKI
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment
Journal Article